INTRODUCTION
Drug solubility is one of an important factors for determine amount and rate of drugs absorption especially in gastrointestinal tract. 1 Drugs with limited solubility in water exhibit low absorption and bioavailability. This condition are due to drug dissolution rates in the gastrointestinal tract. Many methods have been done to improve dissolution characteristics of poorly water-soluble drugs such as reducing particle size, crystal modification, complex with cyclodextrins and self-emulsification.
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Cyclodextrins have been widely used in designing pharmaceutical formulations of dissolve water-insoluble drugs. Several methods have been reported for the formation of drug inclusion complexes with cyclodextrins such as freeze drying, spray drying, co-precipitation, kneading and extrusion. Each of these methods gives different results in particle size,number of complex formations and the amorphous levels of the final product.
3 Formation drugs complexes with cyclodextrin is a prospecting method to be develop because of its ability to increase solubility, wettability, dissolution and bioavailability of orally administered drugs. 4 Recent publications reported that cyclodextrins improved solubility and dissolution of itraconazole, curcumin, repaglanid, mirisetin, and glimepiride. [5] [6] [7] [8] [9] Spray drying method is one method that has been widely used to evaporate solvent for the formation of complex inclusion of poorly water-soluble drugs with β-cyclodextrin. The results of aripiprazole-β-cyclodextrin inclusion complex prepared by spray drying technique showed that this techniques could increase solubility and dissolution rate of aripiprazole. 10 Spray drying technique is also reported as one of the successful methods applied for solvent evaporation of complex inclusion in quercetin, indomethacin and corticosteroid. [11] [12] [13] Glibenclamide is a hypoglycemic compound recommended for type 2 diabetes mellitus. Based on the biopharmaceutical classification system, glibenclamide is classified into class II that has low solubility and a high permeability to cross the gastrointestinal mucosa.
14 Therefore, efforts should be made to improve glibenclamide dissolution to obtain optimal bioavailability. Some of the approaches that have been taken to enhance glibenclamide dissolution include solid dispersion, permeation enhancer and selfemulsification.
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Aims of this study are to characterize, formulate and evaluate inclusion complex tablets of glibenclamide to meet the requirements in Pharmacopeia.
The following inclusion complexes are formulated into tablets with direct compression techniques using primojel and crospovidone as the disintegrant to attempt the increase of glibenclamide dissolution prepared into tablets.
METHODS

Materials
The ingredients used in this study were glibenclamide (PT Phapros), β-cyclodextrin (PT Signa Husada), crospovidone (PT Dexa Medika) and all excipients such as primojel, aerosil, avicel PH-102, and magnesium stearate were obtained from the Pharmacy Laboratory of Islamic University of Indonesia. All ingredients used have a pharmaceutical grade.
Preparation of glibenclamide inclusion complex with β -cyclodextrin
The inclusion complex was conducted by spray drying method using a mini spray dryer (B-290 Buchi). Glibenclamide with β-cyclodextrin with 1: 1 and 1: 2 molar ratio were added in ethanol and stirred until dissolved. The solution was powdered using a spray dryer at an inlet temperature of 1200C until the powder was produced.
Fourier transform infrared (FTIR) spectroscopy
Fourier transform infrared spectra (Nicolet Avatar 360) were used for the study of molecular samples at wavelengths of 400-4000 cm -1 . Glibenclamide, β-cyclodextrin and glibenclamide inclusion complex-β-cyclodextrin were powdered with potassium bromide (KBr 1: 150) and compressed into transparent pellets for analyses.
Scanning electron microscopy (SEM)
Scanning electron microscopy (Jeol JSTM T300 model) was used to analyze the formation of glibenclamide, β-cyclodextrin and glibenclamide-β-cyclodextrin inclusion complexes. Each sample was coated with gold using a fine coater. The sample was glued to the specimen stage and observations are conducted.
Preparation of complex inclusions tablets
Tablets of glibenclamide inclusion complex-β-cyclodextrin were prepared by directcompression techniques containing 5 mg of glibenclamide each tablet. The inclusion Total quantity (mg) 100 100 100 100 100 100 100 100 100 100 complex and all excipients were mixed until homogeneous and subsequently compressed by using a single punch tablet machine (Korsh EK 0). The compositions of each formula is shown in Table 1 .
Tablet evaluation
The weight variation was determined by weighing 20 tablets and calculating the average weight of each tablet, following the requirements of Pharmacopeia. 16 The hardness test was performed ten times using the hardness tester (Vanguard YD-2). Tablet was placed on the tool in a horizontal position and the instrument was calibrated to a position of 0.00. The device was run until the tablet breaks, then read the scale shown on the apparatus. 17 The friability was determined by weighing 20 tablets and put into a friability tester (Erweka TA 200) that rotates for 4 minutes at 25 rpm. Next weighed tablet weight to obtain percent friability. 17 The disintegration time was performed for six tablets in each (Erweka DT 708) type 2. The tablet was placed into a dissolution device containing 900 mL dissolution medium at 37 ± 0.50C with rotation speed of 100 rpm for 45 min. Ten mL sample was taken at 45 minutes. Glibenclamide content level was determined using the HPLC (Waters e-265) at 225 nm wavelength.
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RESULTS
Fourier transform infrared (FTIR) spectroscopy.
Result of inclusion complexes of glibenclamide-β-cyclodextrin 1:1 and the inclusion glibenclamide-β-cyclodextrin 1: 2. FTIR spectra can be presented in the Figure 1 .
Infra red (IR) spectroscopy test aimed to determine interaction of inclusion complexes between glibenclamide and β-cyclodextrin through the occurrence of functional group band shifts on the result of inclusion complex of glibenclamide-β-cyclodextrin. The results of the infrared spectra were analyzed by focusing on areas above 1500 cm -1 or above the fingerprint regions possessed by glibenclamide in β-cyclodextrin complexes to describe the possibility of interaction.
Scanning electron microscopy (SEM).
Scanning electron microscopy analysis was performed on pure glibenclamide, β-cyclodextrin formula and determined by the disintegration tester (Erweka ZT 502) containing distilled water at 37 ± 0.5 0C. Then the time was recorded until all the tablets were pass-through screen at the bottom of the flask in the equipment.
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Content uniformity
Twenty tablets were weighed and powdered.
Then, weighed powder equivalent to 5 mg of glibenclamide and mixed with 2 ml of distilled water and 20 ml of methanol. After that, mixture was filtered and the glibenclamide content was determined using HPLC (Waters e-265).
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Dissolution In Vitro
The test was using dissolution test apparatus 
Tablet evaluation
Result of weight variation, hardness, friability and disintegration time can be illustrated in Table 2 .
and inclusion complex of glibenclamide-β-cyclodextrin (1: 1 and 1: 2 inclusion complex). SEM results were presebted in Figure 2 . SEM was shown to describe the surface morphology of glibenclamide, β-cyclodextrin and both complex formulas inclusion of glibenclamide-β-cyclodextrin. SEM as Figure 2 showed that there was a change of form between pure glibenclamide, glibenclamide-β-cyclodextrin 1: 1 inclusion complex and glibenclamide-β-cyclodextrin 1: 2 inclusion complex.
DISCUSSIONS
Infrared spectra as shown in Figure 1 showed that glibenclamide had a specific absorption at 3300-3370 cm -1 (NH stretching) and 2900 cm -1
(-CH stretching) wavelength. Wavelength at 1710 cm-1 indicate C=O bonds. Strong absorption 
Content uniformity
Result of the determination of active substance in the inclusion complex tablets were shown in Table 3 . Table 4 presented results of in vitro dissolution test at minute 45 (Q45).
In vitro dissolution
at 1520 cm-1 indicated the presence of C=C bonds. Wavelength at 1340 cm-1 indicate the presence of CO and at 1160 cm -1 indicate the peak in SO 2 . 19 The β-cyclodextrin spectra showed that β-cyclodextrin had a widened range at 3413 cm -1 wavelength which are spectrum of OH. The CH bond was seen in the area of 2922 cm -1 and the C-C bond arose in the area of 1157 cm -1 . In the inclusion, complex spectra appeared an O-H spectrum at the 3386 cm -1 and 3383 cm -1 wavelength in the 1: 1 and 1: 2 inclusion complexes. The interaction of hydrogen bond formation in the inclusion complex undergoes a ribbon shift which can be seen in the absorption of O-H group to the right or toward the lower spectra.
A slight shift in the above-infrared spectra was due to an interaction between glibenclamide and β-cyclodextrin with weak bonds. The complex was formed at the time of recrystallization of glibenclamide and β-cyclodextrin that coincide with the solvent evaporation by spray drying process. β-cyclodextrin enveloped the glibenclamide at the time of recrystallization, so that in the visible spectra β-cyclodextrin is more apparent than glibenclamide. The FTIR spectra of inclusion complexes would change because of bending loss and vibrating peaks of the molecule after complexation formation. The complexes did not show additional peaks. It can be explained by the presence of non-covalent interactions. 20, 21 The SEM images showed that pure glibenclamide exhibited a small collection of crystals in various forms, whereas glibenclamide-β-cyclodextrin inclusion complex exhibited an amorphous structure. Inclusion complex showed that β-cyclodextrin envelops glibenclamide. This event occurred at the time of recrystallization by solvent evaporation using spray drying. The inclusion complex happens when glibenclamide enters the β-cyclodextrin hydrophobic cavityresultingthe increased dissolution of glibenclamide. This can be explained that a new complex of β-cyclodextrin and glimepiride are formed. Previous studies shows thatformation of solid inclusion complex between β-cyclodextrin and guest molecules was closely correlated with the varied crystal shapes.
22 Table 2 showed that all formulas meet the requirements of weight variation and mechanical properties (hardness and friability). The hardness test indicate a good mechanical strength and the friability less than 1% indicate that the tablet had a good resistance to external forces like shock and abrasion. The data were fullfil the requirements in the compendial acceptable range. 23 Results of the disintegration time tablets indicate that all tablets meet the requirements (less than 15 minutes or 900 seconds). Increase concentration of primojel and crospovidone will increase the disintegration time of tablets. Primojel can absorb water quickly followed by their ability to expand well in contact with water. These expanding particles cause the tablet to break, so it can contribute to speed up tablet's disintegration time. Crospovidone as a tablet disintegrant had a good capillarity and swelling mechanisms. Water will absorb into the tablet and produce tablet expand. The tablet composing particles will be pressed until the tablet breaks. The disintegration mechanism tablet contain crospovidone as the super disintegrant showed by an initial swelling followed into fine particles. During wetting, the crospovidone in the tablet lost it's post compression deformity in the form of swelling. 23 This reseach shows that primojel has better disintegrant ability than crospovidone.
The content and uniformity of oral solid dosage forms are invariably defined as drug product critical quality attributes. This can impact the safety and efficacy for the patient.
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Concentration of the active substance is one of the requirements that must be fulfilled by a proper tablet preparation. The proper amount of active substance is essential for efficacy and it is crucial to meet the requirements of tablet. Theoretically,glibenclamide tablets contain 5 mg of active ingredient. The requirement of glibenclamide content in a tablet preparation according to British Pharmacopoeia is to provide not less than 90% and not more than 110% of the amount indicated on label. 25 This research showed that all formulas meet the requirements, i.e., glibenclamide tablets containing not less than 90% and not more than 110% of those listed. Based on these results it can be said that the tablet complex are good enough because it deals with right weight uniformity as well.
Dissolution test was carried out to determine the amount of drug dissolution in an appropriate medium. The results of dissolution data establish with Q value which describes the percentage of drugs released at a specific minute. The United States Pharmacopeia (USP) stated that the dissolution (Q value) was not less than 70% at the 45 minutes. The dissolution test as shown in this research showed that all formulas meet the percent requirements of dissolution glibenclamide tablet at 45 minutes, i.e., not less than 70% of those listed. The ability of dissolution will be related to the disintegration capability of the tablet. If the tablets disintegration rapidly, a highernumber of dissolved drugs can be found. This can be seen in formula V which has a faster disintegration time than other formulas.
CONCLUSION
The inclusion complex of glibenclamide-β cyclodextrin successfully used for enhancing the solubility of glibenclamide. The tablets meet the requirements in Pharmacopeia. All tablets of inclusion complex produce good quality tablets and meet the requirements listed on pharmacopeia
